设定基线:在实施肿瘤科医生介导的基因检测之前对浆液性卵巢癌转诊率和结局的7年回顾
该研究回顾了2010至2016年间在玛格丽特公主癌症中心诊断的724例浆液性卵巢癌女性,发现68%被转诊进行遗传咨询,总体检测率为61%。检测者中22%携带BRCA1/2致病性变异,9%携带其他癌症基因变异,24%有致病性变异者无乳腺癌或卵巢癌家族史。转诊和检测率高于既往报道,但仍存在转诊障碍。
要点
- 724例浆液性卵巢癌中68%被转诊遗传咨询,总体检测率61%。
- 检测者中22%有BRCA1/2致病性变异,9%有其他癌症基因变异。
- 24%携带致病性变异者无乳腺癌或卵巢癌家族史。
核心结论
- 浆液性卵巢癌女性的遗传咨询转诊率和检测率高于既往报道,但转诊障碍仍然存在。
- 为最大化检测率并应对患者量增加,诊所可能面临整合新型遗传咨询提供模式。
- 本研究结果可作为更准确的基线,用于比较大规范服务提供变化。
研究设计与样本
- 回顾性研究,从玛格丽特公主癌症中心癌症登记处获取2010年至2016年诊断的浆液性卵巢癌女性名单,并与遗传学数据库交叉比对以确定转诊率和基因检测结局。
主要发现
- 724例浆液性卵巢癌女性中,68%被转诊进行遗传咨询,总体检测率为61%。
- 诊断时年龄较轻和高分级肿瘤的女性转诊率更高。
- 接受检测的女性中,22%发现BRCA1/2致病性变异,9%发现其他癌症基因致病性变异。
- 24%携带致病性变异的女性报告无乳腺癌或卵巢癌家族史。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite guidelines recommending that all women with invasive serous ovarian cancer (SOC) are offered genetic testing, published referral and testing rates have been poor. Many centers have implemented novel genetic counseling service delivery models to increase testing rates. In light of increased awareness and implementation of small process changes at our center, this study aims to establish baseline referral rates and testing outcomes prior to diverging from the traditional model of care. METHODS: A list of women diagnosed with SOC at Princess Margaret Cancer Center (PM) between 2010 and 2016 was obtained from the PM Cancer Registry and cross-referenced against the genetics database to determine referral rates and outcomes of genetic testing. RESULTS: Of 724 women with SOC, 68% were referred for genetic counseling, with an overall testing rate of 61%. Higher referral rates were seen among women with younger ages at diagnosis and high-grade tumors. Of women tested, 22% were found to have a pathogenic variant in BRCA1/2 and 9% in another cancer gene. Notably, 24% of women with a pathogenic variant reported no family history of breast or ovarian cancer. CONCLUSION: Genetic counseling referral and testing rates for women with SOC are higher than previously reported, yet barriers to referral remain. To maximize genetic testing rates and address increasing patient volumes, clinics may be faced with integrating novel genetic counseling delivery models. Findings from this study may serve as a more accurate baseline to which large scale service delivery changes can be compared.
引用
- Armel SR, Volenik A, Demsky R, et al. Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing. Gynecol Oncol. 2020. PMID: 32505554. doi:10.1016/j.ygyno.2020.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。